Serum autoantibodies in the early detection of esophageal cancer: a systematic review
- 702 Downloads
Antibodies against tumor-associated antigens (TAAs) have been found in serum of patients with various types of cancers and may serve as biomarkers for early detection of esophageal cancer as well. This systematic review aims to give an overview about known autoantibodies and their diagnostic value in esophageal cancer. We conducted a systematic literature search in two databases to identify studies which performed serological testing for autoantibodies in esophageal cancer patients and controls. Data on study characteristics and results were extracted independently by two reviewers. Overall, 45 articles reporting the detection of 35 different autoantibodies met the inclusion criteria of this review. The most common antibody detection method was enzyme-linked immunosorbent assay (ELISA), and the most frequently assessed autoantibody was anti-p53, which was tested in 17 studies and for 15 studies of which a meta-analysis was conducted to comprehensively evaluate the diagnostic value. Most antibodies were assessed in only one study, and only few authors have evaluated the diagnostic value of combinations of multiple autoantibodies. For single autoantibodies, specificity was generally very high (median 98.3 %), but sensitivity was mostly rather low (median 26.7 %). For some autoantibody combinations, substantially higher sensitivity at reasonably high levels of specificity could be achieved. Development of extended and optimized multimarker panels of autoantibodies might be a promising approach for esophageal cancer early detection.
KeywordsAutoantibodies Biomarkers Esophageal cancer Early detection Systematic review
This study was supported by grants from the Open Science and Technology Cooperation Projects in Henan province (NO.122106000041) and the General Program of National Natural Science Foundation of China (No.81172086 and No.81372371).
Conflicts of interest
- 14.Zhou SL, Yue WB, Fan ZM, Du F, Liu BC, Li B, Han XN, Ku JW, Zhao XK, Zhang P, Cui J, Zhou FY, Zhang LQ, Fan XP, Zhou YF, Zhu LL, Liu HY, Wang LD. Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma. Dis Esophagus. 2013;27:790–797. doi: 10.1111/dote.12145.
- 18.18 Gao H, Zheng Z, Mao Y, Wang W, Qiao Y, Zhou L, Liu F, He H, Zhao X. Identification of tumor antigens that elicit a humoral immune response in the sera of Chinese esophageal squamous cell carcinoma patients by modified serological proteome analysis. Cancer Lett. 2013;344:54–61. doi: 10.1016/j.canlet.2013.
- 25.Liu W-L, Guo X-Z, Zhang L-J, Wang J-Y, Zhang G, Guan S, Chen Y-M, Kong Q-L, Xu L-H, Li M-Z, Song L-B, Zeng M-S. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer. 2010;10:467. doi: 10.1186/1471-2407-10-467.
- 26.Dong J, Zeng B-H, Xu L-H, Wang J-Y, Li M-Z, Zeng M-S, Liu W-L. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med. 2010;8:81. doi: 10.1186/1479-5876-8-81.
- 49.Kozlowski M, Kovalchuk O, Niklinski J, Chyczewski L, Staroslawska E, Ciechanski A, et al. Circulating anti-p53 antibodies in esophageal cancer patients. Folia Histochem Cytobiol / Pol Acad Sci, Pol Histochem Cytochemical Soc. 2001;39 Suppl 2:173–4.Google Scholar
- 56.Kamei M, Kato M, Mochizuki K, Kuroda K, Sato S, Hashizume S, Yasumoto K, Murakami H, Nomoto K. Serodiagnosis of cancers by ELISA of anti-histone H2B antibody. Biotherapy. 1992;4:17–22.Google Scholar
- 65.Werner S, Chen H, Tao S, Brenner H. systematic review: Serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2014. doi: 10.1002/ijc.28807